Losing a lot of weight is great for your heart, your knees, and your general ability to buy pants. It is less great for your bones. Big weight loss from medication, surgery, or diet can lower bone mass and raise fracture risk, which is the kind of side effect that tends to get noticed eventually.
So Novo Nordisk (NVO) used ObesityWeek 2026 to present data suggesting its investigational amylin-based therapies may support bone health during weight loss. Separately, once-weekly semaglutide significantly reduced body mass index in children with obesity. Two stories, one theme: the company wants to show it is thinking about what happens to the skeleton when the scale goes down.
Amylin Pipeline Protects Bone Health
On Tuesday, Novo Nordisk shared preclinical and clinical findings showing that dual activation of amylin and calcitonin receptors helps preserve bone integrity.
In an eight-week preclinical study modeling postmenopausal bone loss, cagrilintide and CagriSema curbed trabecular bone deterioration compared with untreated and weight-matched controls. Femur trabecular bone volume measured 43% higher with cagrilintide and 40% higher with CagriSema, whereas zenagamtide and semaglutide showed smaller, statistically nonsignificant increases. Small clinical studies in healthy volunteers reinforced these findings.
Here is the mechanistic bit, which is the fun part. Both cagrilintide and zenagamtide suppressed CTX-I, a bone-breakdown biomarker, while the selective amylin agonist NN1213 did not. That points to calcitonin receptor activation as the driver of the protective effect. In other words, it is not just the amylin part doing the work.
Post hoc analyses from the phase 3 REDEFINE 1 trial further evaluated CagriSema over 68 weeks. Bone mineral density did decline alongside substantial weight loss in a 252-participant substudy, but levels remained within normal age and sex ranges. CagriSema and cagrilintide also elevated the bone-formation marker P1NP and key bone-mineralization blood proteins compared with semaglutide alone. Researchers noted that longer follow-up is necessary to assess fracture risk reduction, which is the honest caveat you would expect.
Semaglutide Cuts Pediatric Obesity In Phase 3 Trial
On Monday, Novo Nordisk reported primary results from the phase 3 STEP Young trial, and The New England Journal of Medicine simultaneously published the findings.
The study evaluated once-weekly semaglutide injections alongside diet and exercise in children aged 6 to under 12 with obesity. At week 68, children receiving semaglutide achieved an estimated mean BMI reduction of 17.4%, compared with a 2.2% increase for placebo under the efficacy estimand. Furthermore, 40.4% of adherent children on semaglutide no longer met obesity criteria versus 0% on placebo, with safety matching prior trials.
Zero percent is a striking number, and it is the kind of result that gets pediatricians talking.
NVO Price Action: Novo Nordisk shares were down 2.94% at $40.37 at the time of publication on Tuesday, according to market data.